Extended use of Fluosol emulsion in acute myocardial ischemia treatment

Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):941-9. doi: 10.3109/10731199209119746.

Abstract

An intravenous infusion of Fluosol enhanced significantly the t-PA thrombolysis of the arterio-venous shunt made by insertion of 125I-fibrin clot in rabbits. The plasma radioactivity released through thrombolysis increased in both time and dose-dependent manner after the administration of t-PA. Fluosol in combination with t-PA increased the plasma radioactivity, compared with the t-PA treatment alone at the corresponding dosage. The coronary blood flow was markedly reduced to almost zero after the thrombin injection into narrowed LCX with a clamp in open-chest dogs. An intravenous infusion of Fluosol or Pluronic F-68 solution at a dose of 15 ml/kg significantly shortened the thrombolysis time by intracoronary infusion of urokinase alone. While, little change in the QTc interval of ECG and the plasma CPK-MB activity was observed in the Fluosol group in combination with urokinase, suggesting a myocardial protective action of Fluosol possibly due to its oxygen carrying effect.

MeSH terms

  • Animals
  • Arteriovenous Shunt, Surgical
  • Blood Substitutes / administration & dosage
  • Blood Substitutes / therapeutic use*
  • Dogs
  • Emulsions
  • Female
  • Fibrinolysis / drug effects
  • Fluorocarbons / administration & dosage
  • Fluorocarbons / therapeutic use*
  • Infusions, Intravenous
  • Male
  • Myocardial Ischemia / blood
  • Myocardial Ischemia / therapy*
  • Rabbits
  • Tissue Plasminogen Activator / administration & dosage
  • Urokinase-Type Plasminogen Activator / administration & dosage

Substances

  • Blood Substitutes
  • Emulsions
  • Fluorocarbons
  • fluosol
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator